Article Text

Download PDFPDF
252 Speed to treatment effect in spinal muscular atrophy type 1
  1. Marcus Droege,
  2. Omar Dabbous,
  3. Douglas Feltner,
  4. Aaron Novack,
  5. Imran Kausar,
  6. Melissa Menier,
  7. Douglas Sproule
  1. AvXis, Inc


Background Spinal Muscular Atrophy type 1 (SMA1) is a rapidly progressing disease resulting in death/permanent ventilation by 2 years of age. In ENDEAR, ∼10% of patients died/required permanent ventilation within 2 months after therapy initiation; 39% died/required permanent ventilation by 6 months. This may reflect a non-immediate therapeutic impact related to loading dose schedule. This study explored the rapidity of therapeutic effect of onasemnogene abeparvovec (AVXS-101) gene-replacement therapy (phase 1 study) relative to nusinersen (phase 3 study, ENDEAR).

Methods SMA1 patients were treated with a one-time intravenous AVXS-101 injection (NCT02122952; cohort 2; N=12; 24 months follow-up). Outcomes were event-free survival (EFS, no death/permanent ventilation [AVXS-101: ≥16 hours ventilation/day for >2 weeks; ENDEAR: tracheostomy or ≥16 hours ventilation/day for >21 days]) and motor function improvements (CHOP-INTEND).

Results All patients treated with AVXS-101 survived event-free 24 months post-dose, while 49/80 nusinersen patients showed EFS. Rapid increases in CHOP-INTEND of 9.8 and 15.4 points were observed at 1- and 3-months post–AVXS-101 dose (nusinersen: ≤5-point increase at 2 months after initiation).

Conclusions AVXS-101 appears to improve survival and induce more rapid motor function improvements relative to nusinersen, consistent with rapid restoration of survival motor neuron expression in motor neurons with a single dose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.